Predictive factors for hepatocellular carcinoma in type 1 autoimmune hepatitis.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 18564111.
- Also identified by DOI 10.1111/j.1572-0241.2008.01922.x.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Hepatocellular carcinoma (HCC) is an uncommon but serious occurrence in autoimmune hepatitis. Our objective was to determine predictors for this neoplasm to improve screening strategies. Two hundred twenty-seven patients underwent hepatic ultrasonography and serum alpha fetoprotein determinations at 6-12-month intervals. Nine patients developed HCC (4%), and each had cirrhosis > or =73 months prior to the malignancy (mean, 110 +/- 7 months). By univariate Cox analysis, features at accession associated with a higher risk of HCC were: male gender (Hazard Ratio [HR] 7.0, 95% Confidence Interval [CI] 1.87-26.1, P= 0.004), history of blood transfusion (HR 5.6, 95% CI 1.51-21.1, P= 0.01), thrombocytopenia (HR 7.3, 95% CI 1.89-28.3, P= 0.004), ascites (HR 23.8, 95% CI 4.65-121.8, P= 0.0001), esophageal varices (HR 7.9, 95% CI 1.96-31.8, P= 0.004), and any sign of portal hypertension (HR 19.1, 95% CI 3.91-93.3, P= 0.0003). Features after accession associated with a higher risk of malignancy were: treatment for > or =3 yr (HR 7.6, 95% CI 1.25-18.2, P= 0.02), worsening laboratory tests during corticosteroid therapy (HR 7.6, 95% CI 1.81-32.1, P= 0.006), and cirrhosis for > or =10 yr (HR 8.4, 95% CI 1.69-41.9, P= 0.009). Male gender, features of portal hypertension, history of blood transfusions, immunosuppressive treatment for > or =3 yr, treatment failure, and cirrhosis of > or =10 yr duration identify patients at risk for HCC. These risk factors should focus screening in autoimmune hepatitis.
Medical subject headings
- Carcinoma, Hepatocellular
- Hepatitis, Autoimmune
- Liver Neoplasms